PSS56 PRESCRIPTION REFILLS AND HEALTH CARE COSTS ASSOCIATED WITH TOPICAL METRONIDAZOLE IN MEDICAID ENROLLED PATIENTS WITH ROSACEA  by Jayawant, SS et al.
(OR = 0.94, IC95%: 0.88–0.99). CONCLUSIONS: Parents/
caregivers have serious worries to use corticosteroids in chil-
dren with ﬂares in face/neck, with mild severity and in younger
childrens.
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OBJECTIVES: Alternative treatments are available to relieve
people with moderate and severe psoriasis in states of remission
and relapse. The purpose of this study was characterise treat-
ment satisfaction with alternative therapies in a survey across
nine European countries. Speciﬁcally, to determine relative
treatment satisfaction with etanercept. METHODS: Up to 120
subjects with moderate or severe psoriasis were identiﬁed in
each of nine countries: Austria (n = 50), France (n = 120),
Germany (n = 120), Italy (n = 120), The Netherlands (n = 75),
Norway (n = 43), Spain (120), Sweden (n = 50) and the UK
(n = 120). Patients were identiﬁed through their dermatologist,
and selected in order to give a sample that represented the alter-
native current treatment regimens, including: biologics such as
etanercept, systemic therapies, and light therapy (PUVA).
Patients were excluded if they had psoriatic arthritis. Treatment
severity was classiﬁed in two ways. Firstly, self-reported sever-
ity, and secondly; percent bodily coverage with psoriatic
plaques. Satisfaction with treatment was deﬁned as a response
of either “satisﬁed” or “very satisﬁed” with treatment. Treat-
ments were excluded from the analysis where <20 observations
were available. Fumaderm was excluded as it was not relevant
for all countries. RESULTS: There were 818 respondents in
total; 45% male. Their mean age was 40.1 years (sd 11.8), and
the median time since diagnosis was 12.0 years (IQR 4.0 to
21.0). The frequency of psoriasis severity for people with <3%,
3%–10%, and >10% bodily coverage was 74 (9%), 421
(52%), and 323 (39%) people, respectively. Overall, 67% of
people expressed satisfaction with psoriasis treatment (64%
moderate and 71% severe; p = 0.117). For people with moder-
ate psoriasis, 3% to 10% coverage, the following percent of
people reported satisfaction with treatment: cyclosporine 60%
(52 of 87), PUVA 63% (54 of 86), methotrexate 65% (53 of
81) and etanercept 78% (21 of 27; p = 0.387). For people with
severe psoriasis, >10% coverage, treatment satisfaction was
achieved as follows: methotrexate 59% (31 of 53), PUVA 62%
(28 of 45), cyclosporine 70% (19 of 27), remicade 71% (20 of
28) and etanercept 94% (46 of 49; p = 0.001). People with
severe psoriasis were more satisﬁed with treatment with etan-
ercept than moderate psoriasis (78% vs. 94%; p = 0.088).
These ﬁndings were consistent across the nine countries. CON-
CLUSIONS: The majority of people with moderate and severe
psoriasis expressed satisfaction with their current treatment.
Treatment satisfaction with etanercept in both groups was
more frequent when using etanercept (78% and 94%,
respectively).
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OBJECTIVES: To examine ustekinumab’s effects on work limi-
tations, productivity, and the number of workdays missed due to
psoriasis. METHODS: In PHOENIX 2 (a Phase 3 trial), 1,230
patients were randomized 1:1:1 to ustekinumab (45 mg or 90 mg
administered at weeks 0, 4, and q12 weeks), or placebo. Patients
randomized to placebo crossed over to receive ustekinumab
45 mg or 90 mg at week 12. Work limitations were assessed
using the Work Limitations Questionnaire (WLQ). WLQ assesses
work limitations due to health in four areas: physical, time
management, mental-interpersonal, and output demands. Each
demand is scored from 0 (limited none of the time) to 100
(limited all of the time). Productivity was assessed using a Visual
Analog Scale (0–10). The number of workdays missed due to
psoriasis in the last 4 weeks was evaluated at baseline and week
12. RESULTS: At baseline, 75% of patients were employed. At
week 12, the mean changes in scores of physical, time manage-
ment, mental-interpersonal, and output demands were -6.33,
-7.85, -7.67 and -6.09, respectively, in ustekinumab-treated
patients, compared to mean changes of -0.20, 0.74, 1.11, and
1.08, respectively, in the placebo group (p < 0.01, each compari-
son of ustekinumab vs. placebo). The mean change in produc-
tivity score from baseline to week 12 was -2.55 for the combined
ustekinumab group vs 0.0 for the placebo group (p < 0.001). The
mean reduction from baseline to week 12 in the number of
workdays missed in the last 4 weeks in the combined usteki-
numab group was 0.2 days, compared to a reduction of 0.04
days in the placebo group. On an annual basis, this represents a
reduction of 2.1 workdays missed in the ustekinumab group vs.
the placebo group. Patients in the placebo group who crossed
over to ustekinumab at week 12 achieved similar improvements
at week 24 in work limitations, productivity, and workdays
missed compared to patients initially randomized to usteki-
numab. CONCLUSIONS: Ustekinumab signiﬁcantly improved
work limitations, increased productivity, and reduced workday
loss in moderate to severe psoriasis patients.
SENSORY SYSTEMS DISORDERS—Health Care Use &
Policy Studies
PSS56
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OBJECTIVES: Reﬁll adherence to medications and health care
costs are important factors to consider while making informed
decision regarding treatment of rosacea patients. The objective of
this study was to examine predictors of number of reﬁlls related
to topical metronidazole and total health care costs in rosacea
patients. METHODS: This study utilized a longitudinal cohort
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design and followed rosacea patients enrolled in North Carolina
Medicaid and who were prescribed at least one study medication
(topical metronidazole, adapalene, azelaic acid, permethrin, and
sulfacetamide). Patients’ demographic characteristics, number of
metronidazole reﬁlls, and different components of health care
costs were examined. Multivariate regression analyses were used
to examine factors associated with prescription reﬁlls and health
care costs. RESULTS: Out of the total 2587 rosacea patients,
the majority (~69%, n = 1771) had 1 or more prescriptions for
topical metronidazole. Most of the patients in this study were
Whites (73%). After controlling for other variables, increasing
age was associated with higher number of metronidazole reﬁlls
and health care costs (both p < 0.001). As compared to Whites,
African American patients had signiﬁcantly lower number of
metronidazole reﬁlls (p < 0.001). As compared to Whites,
African American and other races were associated with an 8.6%
and 10.3% decrease in total health care costs respectively (both
p < 0.001). An increase in number of metronidazole reﬁlls was
not associated with an increase in health care costs. CONCLU-
SIONS: Patients’ race was signiﬁcantly associated with the
number of topical metronidazole reﬁlls. Patients’ health care
costs increased with increasing age and charges paid for prescrip-
tions. Topical metronidazole seems to be an economically fea-
sible treatment option for Medicaid-enrolled patients with
rosacea.
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OBJECTIVES: To assess the use of biologicals for psoriasis
according to NICE technology appraisal 103 and assess actual
treatment practice within the NHS. METHODS: To date 13 UK
sites have enrolled into the chart review. Site selection was based
upon recruiting three centres with prescribers of biologicals
across nine geographical locations. Information was collected
for patients initiated on a biological between August 2006 and
December 2007 for plaque psoriasis. Patients were excluded if
they had a diagnosis of psoriatic arthritis. The data was collated
on demographics, co-morbidities, treatment courses, Psoriasis
Area Severity Index (PASI) and Dermatology Life Quality Index
(DLQI), and reasons for stopping treatment. Data was analysed
to ascertain adherence to NICE, and to explore regimens used in
practice and discontinuation rates. RESULTS: Recruitment is
being completed. This information will be reported as a full
dataset in the poster. Thus far data has been collected for 66
patients across 7 centres. The average age of patients reported
was 46 years. Eight-one percent of patients were initiated on
etanercept 25 mg twice weekly, 3% on etanercept 50 mg twice
weekly, and 8% on efalizumab. Of those patients who initiated
etanercept 25 mg twice weekly, the average length of the ﬁrst
course of treatment was 169 days (approximately 24 weeks).
Patients discontinued etanercept treatment for various reasons
including adverse events and lack of efﬁcacy. Fourteen switched
to efalizumab following ﬁrst etanercept course. Many patients
did not have PASI and DLQI recorded 12 weeks post treatment
commencement. CONCLUSIONS: Many of the NICE criteria
for prescribing biologicals have been followed; however there are
some areas which require focus including recording of PASI and
DLQI scores within three months. The review also showed that
the intermittent dosage assumed by NICE in the appraisal of
these drugs may not be realistic and modiﬁcation is needed in
further technology appraisals.
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OBJECTIVES: Evaluation of quality of care of leg ulcers in the
area of Hamburg, assessment of treatment with respect to
guidelines, recording of patients’ quality of life and burden of
treatment in the area of this community. METHODS: Potential
criteria for the evaluation of quality of care were derived from
the German AWMF-guideline and relevant international guid-
ance. Wound experts (physicians and nurses) derived 20 prior-
ity criteria and indicators which deﬁne “optimal treatment” in
a national Delphi consensus. A total score for quality of care
was developed, ranging from 0–100 (no to perfect quality of
care). Then, a representative sample of n = 520 patients with
chronic leg ulcers of any origin was consecutively drawn.
Patients were approached in wound clinics, ofﬁce-based prac-
tices, nursing homes, home care services and special centres for
homeless and drug addicts, thus including a large spectrum of
220 health care providers. All patients were interviewed, all
wounds photographed and examined by trained wound
experts. Patients were asked to ﬁll a questionnaire addressing
quality of life, prior therapy and health services/care.
RESULTS: Data of 502 patients were analysed, including leg
ulcers with venous (63%), mixed (23%), vasculitic (2%) and
other (12%) pathogenesis. A high proportion of patients
(78.6%) were treated with modern wound dressings. Pain and
compression therapy was mainly in accordance with guidelines.
However, deﬁcits were detected for diagnostics (e.g. angiology,
biopsies, pain measurement) and concomitant wound treat-
ments. A high proportion of patients still had a markedly
impaired quality of life. The mean total score for quality of
care was below 60. CONCLUSIONS: In spite of mostly “lege
artis” topical treatment, many patients in North Germany are
not treated in accordance to relevant guidelines. The quality of
care scoring method developed was shown to be a sensitive tool
for health services research and evaluation.
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IMPACT OF HEALTH CARE REGULATION ON
PROSTAGLANDIN ANALOGUE PRESCRIBING IN
5 EUROPEAN COUNTRIES
De Natale R1, Berdeaux G2
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OBJECTIVES: To compare the evolution of prostaglandin ana-
logue (PGA) and beta-blocker (BB) prescriptions in ﬁve European
countries in the context of the health care regulation environ-
ment. METHODS: Data from different sources were gathered: 1)
1998–2003 prescriptions delivered by the central pharmacy of
the Padova geographical area; 2) IMS data (1995–2006) from
France, Germany, Italy, Spain and the United-Kingdom; and 3)
an extraction of glaucoma-treated patients from the UK-GPRD.
Drugs were grouped in 3 classes: PGA, BB and others. Yearly
market shares were calculated. Treatment persistence survival
curves were estimated from the Italian and UK data and the three
drug groups were compared using the Cochran Mantel Haenszel
test. RESULTS: According to the Padova data, BB market share
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